About This Briefing Desk

What Private Peptides is

Private Peptides is an independent editorial briefing on the published research covering three peptides studied for metabolic regulation and weight management: AOD-9604, MOTS-c, and retatrutide, read across a single frame — from lipolytic fragments to incretin agonists. Each page is organized the way a clinician reads an unfamiliar case: what the compound is, what the record shows, what to watch, and what remains genuinely unknown.

The three compounds do not share a mechanism; they share a research classification and a common evidentiary problem — how far does an interesting laboratory or preclinical finding actually reach into confirmed human benefit? AOD-9604 answered that question with a completed, negative human trial program. MOTS-c has not yet had the chance to answer it in humans at all. Retatrutide is partway through answering it, with a Phase 2 record that looks strong and a Phase 3 verdict still pending. Reading the three side by side, on the comparison page, makes that spread visible in a way that reading any one compound alone does not.

How it is compiled

Three rules govern this desk.

First, every factual claim is tied to a numbered, checkable source. Peer-reviewed journal articles, clinical-trial publications, and structural or mechanistic studies, each with a DOI or PubMed link where available, are collected on the shared references page and cited by number throughout the site.

Second, evidence is described at the strength it actually has. A finding from a 32-rabbit preclinical model is labeled as such. A finding from a 338-person Phase 2 trial is labeled as such. An observational biomarker association in 94 patients is never described as if it were an interventional trial result. Where a compound's human trial record failed to demonstrate an effect, this desk says that plainly rather than emphasizing the preclinical data that preceded it.

Third, community-reported experience is carried, but clearly separated from the research record. Where research-use communities report benefits or side effects, this desk includes them — labeled, every time, as anecdotal, not clinical evidence — because the questions people actually bring to these compounds are worth acknowledging honestly, even when the honest answer is "this has not been studied in humans."

What it is not

Private Peptides is not a pharmacy, clinic, telehealth service, or vendor of any kind. It does not sell, source, or broker any compound, and has no affiliate or referral relationship with any supplier, manufacturer, or telehealth provider. It does not employ clinicians, diagnose any condition, or recommend a dose, schedule, or route of administration for any person.

None of the three compounds covered here is an approved medicine for self-directed human use; retatrutide alone is under active pharmaceutical development, in registered clinical trials. Readers with a clinical question about any of these compounds should consult a licensed healthcare provider in their own jurisdiction. Editorial correspondence — citation corrections, newly published trial results, or regulatory updates — can be sent through the contact page; this desk reads that correspondence carefully and cannot respond to requests for medical advice.